Drugs / DM001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06475937 | Oct 2024 → Aug 2026 overdue | breast neoplasm, non-small cell lung carcinoma | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DM001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06475937 ↗ |
| Route | Intravenous | “DM001 is sterile yellowish-green lyophilized powder for IV infusion.” NCT06475937 ↗ |